Abstract
Ageing is associated with a decline in immune competence termed immunosenescence. In the elderly, this process results in an accumulation of differentiated 'effector' phenotype memory T cells, predominantly driven by Cytomegalovirus (CMV) infection. Here, we asked whether CMV also drives immunity towards a senescent profile in healthy young adults. One hundred and fifty-eight individuals (mean±SD; age 21±3 years, body mass index 22.7±2.7 kg m2) were assessed for CMV serostatus, the numbers/proportions of CD4+ and CD8+ late differentiated/effector memory cells (i.e. CD27-CD28 -/CD45RA+), plasma interleukin-6 (IL-6) and antibody responses to an in vivo antigen challenge (half-dose influenza vaccine). Thirty percent (48/158) of participants were CMV+. A higher lymphocyte and CD8+ count (both p<0.01) and a lower CD4/CD8 ratio (p<0.03) were observed in CMV+ people. Eight percent (4/58) of CMV+ individuals exhibited a CD4/CD8 ratio <1.0, whereas no CMV- donor showed an inverted ratio (p<0.001). The numbers of CD4+ and CD8+CD27-CD28-/CD45RA+ cells were-fourfold higher in CMV+ people (p<0.001). Plasma IL-6 was higher in CMV+ donors (p<0.05) and showed a positive association with the numbers of CD8+CD28- cells (p<0.03). Finally, there was a significant negative correlation between vaccine-induced antibody responses to the A/Brisbane influenza strain and CMV-specific immunoglobulin G titres (p<0.05). This reduced vaccination response was associated with greater numbers of total CD8+ and CD4+ and CD8 +CD27-CD28-/CD45RA+ cells (p<0.05). This study observed marked changes in the immune profile of young adults infected with CMV, suggesting that this virus may underlie rudimentary aspects of immunosenescence even in a chronologically young population.
Original language | English |
---|---|
Pages (from-to) | 287-297 |
Number of pages | 11 |
Journal | Age (Dordrecht, Netherlands) |
Volume | 36 |
Issue number | 1 |
DOIs | |
Publication status | Published - Feb 2014 |
Keywords
- Cytomegalovirus
- Immunosenescence
- Interleukin-6
- Vaccination efficacy